Stock Review: Inverness Medical Innovations IMA

Inverness Medical Innovations, Inc. engages in the development, manufacture, and marketing of in vitro diagnostic products for the over the counter pregnancy and fertility/ovulation, and the professional diagnostic test markets worldwide.

It operates in three segments:

• Consumer Diagnostic Products, Vitamins
  
• Nutritional Supplements, and
  
• Professional Diagnostic Products.

The Consumer Diagnostic Products segment provides Clearblue home pregnancy and fertility/ovulation prediction tests; Clearblue Easy Digital pregnancy and fertility/ovulation prediction tests; the Clearblue Easy Digital brand, the digital pregnancy test; Clearblue Easy Fertility Monitor, the hormone-based reusable monitoring devices; pregnancy and fertility/ovulation prediction products; and Persona, a diagnostic monitoring device. The Vitamins and Nutritional Supplements segment markets various vitamins and nutritional supplements. This segments products include Stresstabs, a B-complex vitamin with added antioxidants; Ferro-Sequels, a time-release iron supplement; Protegra, an antioxidant vitamin and mineral supplement; Posture-D, a calcium supplement; SoyCare, a soy supplement for menopause; ALLBEE, a line of B-complex vitamins; and Z-BEC, a zinc supplement with B-complex vitamins and added antioxidants. The Professional Diagnostic Products segment offers membrane test products for pregnancy, drugs of abuse, RSV, Influenza A/B, strep throat, HIV, C.difficile, Lyme disease, chlamydia, H.pylori, fecal occult blood, D-dimer, mononucleosis, and rubella; enzyme linked immunosorbent assay tests for various infectious and autoimmune diseases, as well as a automated instrumentation for processing ELISA assays, as well as AtheNA Multi-Lyte test systems, IFA/Serology products, and Ischemia tests. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.